Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Avelumab (Primary) ; Axitinib (Primary) ; Crizotinib (Primary) ; Ivuxolimab (Primary) ; Lorlatinib (Primary) ; Pemetrexed (Primary) ; Talazoparib (Primary) ; Utomilumab (Primary) ; Vidutolimod (Primary) ; Vidutolimod (Primary)
Indications Carcinoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; Registrational
Sponsors Pfizer

03 Apr 2024 Planned End Date changed from 21 May 2025 to 30 Sep 2026.
03 Apr 2024 Planned primary completion date changed from 21 May 2025 to 30 Sep 2026.
03 Apr 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com